Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors - Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035515

Enrollment

100

Registered

2019-01-18

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients using Proton pump inhibitors (PPIs)

Interventions

alendronate 35mg per week for one year alfacalcidol 1microgram per day for one year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Osteoporotic patients using proton pump inhibitors

Exclusion criteria

Exclusion criteria: Patients with esophageal transit and delay disorder Patients can't be instructed to remain upright for >30 min bisphosphonate allergy Hypocalcemia Serious renal disorder or Serum creatinine >1.5 mg/dL Severe liver injury Upper GI endoscopy findings were not analyzed Doctor judged inappropriate as a subject

Design outcomes

Primary

Measure	Time frame
Bone mass increase effect	—

Secondary

Measure	Time frame
Incidence of fractures Transition of bone turnover marker Upper gastrointestinal endoscopy results Compliance Safety	—

Countries

Japan

Contacts

Public ContactDaisuke Asaoka

Juntendo University Hospital Department of Gastroenterology

daisuke@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026